Measuring adrenal autoantibody response: Interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies

Clinical Immunology

Volumn 140, Issue 3, 2011, Pages 291-299

  Falorni, Alberto ^a   Chen, Shu ^b   Zanchetta, Renato ^c   Yu, Liping ^d   Tiberti, Claudio ^e   Bacosi, Maria Luisa ^a   Furmaniak, Jadwiga ^b   Bini, Vittorio ^a   Dotta, Francesco ^f   Eisenbarth, George S ^d   Rees Smith, Bernard ^b   Betterle, Corrado ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b RSR LTD   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF COLORADO DENVER   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF SIENA   (Italy)

Author keywords

Adrenal insufficiency; Autoimmune Addison's disease; Autoimmune polyendocrine syndrome; Radioimmunoassay; Standardization

Indexed keywords

21 HYDROXYLASE AUTOANTIBODY; AUTOANTIBODY; AUTOANTIGEN; IODINE 125; SULFUR 35; UNCLASSIFIED DRUG;

ADDISON DISEASE; ADRENAL GLAND; ADRENAL INSUFFICIENCY; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; INTERRATER RELIABILITY; ISOTOPE LABELING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ADDISON DISEASE; ADULT; ANTIBODY FORMATION; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; HUMANS; LABORATORIES, HOSPITAL; MALE; MIDDLE AGED; OBSERVER VARIATION; RADIOIMMUNOASSAY; REPRODUCIBILITY OF RESULTS; STEROID 21-HYDROXYLASE; YOUNG ADULT;

EID: 80051794839     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.04.012     Document Type: Article

References (41)

1. Laureti S., Vecchi L., Santeusanio F., Falorni A. Is the prevalence of Addison's disease underestimated?. J. Clin. Endocrinol. Metab. 1999, 84:1762.
2. Løvås K., Husebye E.S. High prevalence and increasing incidence of Addison's disease in western Norway. Clin. Endocrinol. (Oxf.) 2002, 56:787-791.
3. Oelkers W. Adrenal insufficiency. N. Engl. J. Med. 1996, 335:1206-1212.
4. Laureti S., Santeusanio F., Falorni A. Recent advances in the diagnosis and therapy of primary adrenal insufficiency. Curr. Med. Chem. Immun. End. Metab. Agents 2002, 2:251-272.
5. Betterle C., Dal Pra C., Mantero F., Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr. Rev. 2002, 23:327-364.
6. Falorni A., Brozzetti A., Calcinaro F., Marzotti S., Santeusanio F. Recent advances in adrenal autoimmunity. Exp. Rev. Clin. Endocrinol. Metab. 2009, 4:333-348.
7. Boscaro M., Betterle C., Volpato M., Fallo F., Furmaniak J., Rees-Smith B., Sonino N. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity block in vivo. J. Clin. Endocrinol. Metab. 1996, 181:2801-2804.
8. Betterle C., Dal Pra C., Pedini B., Zanchetta R., Albergoni M.P., Chen S., Furmaniak J., Rees-Smith B. Assessment of adrenocortical function and autoantibodies in a baby born to a mother with autoimmune polyglandular syndrome type 2. J. Endocrinol. Invest. 2004, 27:618-621.
9. Falorni A., Laureti S., De Bellis A., Zanchetta R., Tiberti C., Arnaldi G., Bini V., Beck-Peccoz P., Bizzarro A., Dotta F., Mantero F., Bellastella A., Betterle C., Santeusanio F. Italian Addison Network Study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 2004, 89:1598-1604.
10. Betterle C., Volpato M., Rees Smith B., Furmaniak J., Chen S., Greggio N.A., Sanzari M., Tedesco F., Pedini B., Boscaro M., Presotto F. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison's disease. J. Clin. Endocrinol. Metab. 1997, 82:932-938.
11. Betterle C., Volpato M., Rees Smith B., Furmaniak J., Chen S., Zanchetta R., Greggio N.A., Pedini B., Boscaro M., Presotto F. II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease. J. Clin. Endocrinol. Metab. 1997, 82:939-942.
12. Brewer K.W., Parziale V.S., Eisenbarth G.S. Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency. N. Engl. J. Med. 1997, 337:202.
13. Laureti S., De Bellis A., Muccitelli V.I., Calcinaro F., Bizzarro A., Rossi R., Bellastella A., Santeusanio F., Falorni A. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. J. Clin. Endocrinol. Metab. 1998, 83:3507-3511.
14. De Bellis A., Falorni A., Laureti S., Perrino S., Coronella C., Forini F., Bizzarro E., Bizzarro A., Abbate G., Bellastella A. Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. J. Clin. Endocrinol. Metab. 2001, 86:675-678.
15. Barker J.M., Ide A., Hostetler C., Yu L., Miao D., Fain P.R., Eisenbarth G.S., Gottlieb P.A. Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population. J. Clin. Endocrinol. Metab. 2005, 90:128-134.
16. Coco G., Dal Pra C., Presotto F., Albergoni M.P., Canova C., Pedini B., Zanchetta R., Chen S., Furmaniak J., Rees Smith B., Mantero F., Betterle C. Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J. Clin. Endocrinol. Metab. 2006, 91:1637-1645.
17. Betterle C., Scalici C., Presotto F., Pedini B., Moro L., Rigon F., Mantero F. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J. Endocrinol. 1988, 117:467-475.
18. Winqvist O., Karlsson F.A., Kämpe O. 21-hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 1992, 339:1559-1562.
19. Bednarek J., Furmaniak J., Wedlock N., Kiso Y., Baumann-Antczak A., Fowler S., Krishnan H., Craft J.A., Rees-Smith B. Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison's disease. FEBS Lett. 1992, 309:51-55.
20. Colls J., Betterle C., Volpato M., Prentice L., Rees Smith B., Furmaniak J. Immunoprecipitation assay for autoantibodies to steroid 21-hydroxylase in autoimmune adrenal diseases. Clin. Chem. 1995, 41:375-380.
21. Falorni A., Nikoshkov A., Laureti S., Grenbäch E., Hulting A.L., Casucci G., Santeusanio F., Brunetti P., Luthman H., Lernmark Å. High diagnostic accuracy for idiopathic Addison's disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J. Clin. Endocrinol. Metab. 1995, 80:2752-2755.
22. Tanaka H., Perez M.S., Powell M., Sanders J.F., Sawicka J., Chen S., Prentice L., Asawa T., Betterle C., Volpato M., Rees Smith B., Furmaniak J. Steroid 21-hydroxylase autoantibodies: measurements with a new immunoprecipitation assay. J. Clin. Endocrinol. Metab. 1997, 82:1440-1446.
23. Falorni A., Laureti S., Nikoshkov A., Picchio M.L., Hallengren B., Vandewalle C.L., Gorus F.K., Belgian Diabetes Registry, Tortoioli C., Luthman H., Brunetti P., Santeusanio F. 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Clin. Exp. Immunol. 1997, 107:341-346.
24. Seissler J., Schott M., Steinbrenner H., Peterson P., Scherbaum W.A. Autoantibodies to adrenal cytochrome P450 antigens in isolated Addison's disease and autoimmune polyendocrine syndrome type II. Exp. Clin. Endocrinol. Diabetes 1999, 107:208-213.
25. Betterle C., Volpato M., Pedini B., Chen S., Rees Smith B., Furmaniak J. Adrenal-cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease: comparison of immunofluorescence and immunoprecipitation assays. J. Clin. Endocrinol. Metab. 1999, 84:618-622.
26. Do Carmo Silva R., Kater C.E., Dib S.A., Laureti S., Forini F., Cosentino A., Falorni A. Autoantibodies against recombinant human steroidogenic enzymes 21-hydroxylase, side-chain cleavage and 17alpha-hydroxylase in Addison's disease and autoimmune polyendocrine syndrome type III. Eur. J. Endocrinol. 2000, 142:187-194.
27. Myhre A.G., Undlien D.E., Løvås K., Uhlving S., Nedrebø B.G., Fougner K.J., Trovik T., Sørheim J.I., Husebye E.S. Autoimmune adrenocortical failure in Norway; autoantibodies and human leukocyte antigen class II associations related to clinical features. J. Clin. Endocrinol. Metab. 2002, 87:618-623.
28. Erichsen M.M., Løvås K., Skinningsrud B., Wolff A.B., Undlien D.E., Svartberg J., Fougner K.J., Berg T.J., Bollerslev J., Mella B., Carlson J.A., Erlich H., Husebye E.S. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J. Clin. Endocrinol. Metab. 2009, 94:4882-4890.
29. Fichna M., Fichna P., Gryczyńska M., Walkowiak J., Zurawek M., Sowiński J. Screening for associated autoimmune disorders in Polish patients with Addison's disease. Endocrine 2010, 37:349-360.
30. Altman D.G. Practical statistics for medical research 1995, 403-409. Chapman, Hall, London.
31. Fleiss J.L., Cuzick J. The reliability of dichotomous judgements: unequal numbers of judges per subject. Appl. Psychol. Meas. 1979, 3:537-542.
32. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
33. Passing H., Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J. Clin. Chem. Clin. Biochem. 1983, 21:709-720.
34. Brown R.H., Durbin J., Evans J.M. Tecniques for testing the constancy of regression relationship over time. JRSS ser B 1975, 37:149-163.
35. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet I 1986, 307-310.
36. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979, 86:420-427.
37. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
38. Verge C.F., Stenger D., Bonifacio E., Colman P.G., Pilcher C., Bingley P.J., Eisenbarth G.S. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes. Diabetes 1998, 47:1857-1866.
39. Bingley P.J., Bonifacio E., Mueller P.W. Participating Laboratories, Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003, 52:1128-1136.
40. Törn C., Mueller P.W., Schlosser M., Bonifacio E., Bingley P.J. Participating Laboratories, Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008, 51:846-852.
41. Schlosser M., Mueller P.W., Törn C., Bonifacio E., Bingley P.J. Participating Laboratories, Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010, 53:2611-2620.